Taurus Asset Management LLC Buys 1,130 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Taurus Asset Management LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,125 shares of the biopharmaceutical company's stock after acquiring an additional 1,130 shares during the period. Taurus Asset Management LLC's holdings in Regeneron Pharmaceuticals were worth $12,199,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in REGN. Geode Capital Management LLC grew its position in Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after acquiring an additional 155,369 shares during the period. Franklin Resources Inc. raised its holdings in Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock worth $1,456,864,000 after purchasing an additional 149,124 shares during the last quarter. Loomis Sayles & Co. L P lifted its position in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after purchasing an additional 393,997 shares during the period. Amundi boosted its stake in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after purchasing an additional 487,489 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $802,036,000. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on REGN shares. Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 4th. Canaccord Genuity Group dropped their price objective on Regeneron Pharmaceuticals from $170.00 to $150.00 and set a "hold" rating for the company in a report on Thursday. Robert W. Baird reduced their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. Finally, Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research note on Monday, January 27th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $963.56.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN traded up $13.88 during midday trading on Friday, reaching $563.16. The company's stock had a trading volume of 827,663 shares, compared to its average volume of 711,859. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market cap of $61.57 billion, a P/E ratio of 14.71, a P/E/G ratio of 2.34 and a beta of 0.44. The business's 50 day moving average price is $647.99 and its two-hundred day moving average price is $743.86. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company posted $11.86 EPS. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. Regeneron Pharmaceuticals's payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.